Analysis of Counterfeit Antidiabetic Drugs by UHPLC with the Agilent 1220 Infinity Mobile LC
Total Page：16
File Type：pdf, Size：1020Kb
Analysis of Counterfeit Antidiabetic Drugs by UHPLC with the Agilent 1220 Infinity Mobile LC Application Note Small Molecule Pharmaceuticals & Generics Author Abstract Sonja Schneider This Application Note shows the analysis of antidiabetic drugs of the sulfonylurea Agilent Technologies, Inc. class using the Agilent 1220 Infinity Gradient LC system with diode array detector Waldbronn, Germany (DAD). Both HPLC and UHPLC methods revealed excellent precision, accuracy and linearity as well as comparable limits of detection and quantification. With retention time and spectral confirmation, chemical antidiabetic substances could be identified and quantified in antidiabetic drugs and dietary supplements. mAU 200 TCM drug 1 175 150 TCM drug 2 125 100 OTC diabetic drug 75 50 Standards 25 0 0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 min Introduction O O O S The production of counterfeit drugs is a O O O NH O huge problem in developing countries, H especially in parts of Africa and Asia1, HH H where approximately 50% of all sold drugs are fake. According to the Food and Glipizide Gliclazide Drug Administration (FDA), counterfeit drugs comprise approximately 10% of the global medicine market. Counterfeiting O O O is found in both branded and generic H3C O O O O drugs, containing the wrong amount or HH 2 the wrong active ingredient . Chemical O drugs can be found in adulterated dietary H HH supplements, where no chemical active H ingredient is allowed. Cl GlibenclamideGlimepiride This Application Note shows the analysis of six antidiabetic drugs of the sulfonylurea class using the 1220 O Infinity Gradient LC system with DAD. O O O Figure 1 displays the six sulfonylurea O OH drugs: glipizide, gliclazide, glibenclamide, O HH glimepiride, gliquidone, and repaglinide. H These sulfonylurea drugs are commonly used in clinics to treat type II diabetes mellitus patients. The drugs stimulate Gliquidone Repaglinide the pancreas to release insulin, which Figure 1. Chemical antidiabetic drug substances of the sulfonylurea class. lowers blood sugar. Approximately 90% of diabetes patients suffer from type II diabetes, which represents noninsulin dependent diabetes mellitus2. The analysis of type II antidiabetes drugs is very important to ensure their safety and efficacy. The 1220 Infinity Gradient LC system with DAD enables the analysis of potentially counterfeit and adulterated antidiabetic drugs and dietary supplements to quantify and identify the active chemical ingredients. The Agilent 1220 Infinity Mobile LC Solution is a robust and rugged system for on-site measurement because it is resistant against shocks or vibrations during transportation. The 1220 Infinity Mobile LC Solution can be used in a mobile laboratory as for on-site drug analysis. 2 Experimental Software Results and Discussion The Agilent 1220 Infinity Gradient • Agilent OpenLAB CDS The antidiabetic drug standards were LC system with DAD (G4294B) was ChemStation Edition for LC & LC analyzed under HPLC conditions equipped with a dual gradient pump MS Systems, Rev. C.01.04 [35] according to Yao et al.2, see Figure 2. Six with integrated degasser, autosampler, consecutive runs were analyzed for their column compartment, and the diode array • Agilent OpenLAB CDS 3D UV precision regarding retention time and detector. For transportation, the LC can be Add-On software area. The relative standards deviation mounted on a transportation plate, 1220 (RSD) of retention time and area was Infinity Mobile Upgrade Kit (G4292A). found to be excellent, below 0.04% and 0.22% respectively. Sample Antidiabetics standards of glipizide, Chromatographic Conditions gliclazide, glibenclamide, glimepiride, and repaglinide and the excipients 4.6 × 150 mm, 5 µm 3 × 50 mm, 1.8 µm silica, starch, soluble, talc, magnesium stearate, cellulose, polyvinylpyrrolidone, Solvent Methanol:10 mM phosphate buffer, Methanol:10 mM phosphate buffer, pH 3 (70:30) pH 3 (65:35) and hypromellose were purchased from Sigma-Aldrich, St. Louis, MO, Flow rate 1 mL/min 1.5 mL/min USA. Gliquidone was purchased from Isocratic Stop time – 25 minutes Stop time – 2 minutes LGC Standards, Teddington, UK. The Injection volume 10 µL 1.4 µL antidiabetic drug and the dietary Temperature TCC RT 60 °C supplements were obtained through DAD 230 nm/16 nm Ref.: off 230 nm/16 nm Ref.: off online pharmacies in China. Peak width > 0.025 minutes 0.0063 minutes (0.5 second response time) (10 Hz) (0.13 second response time) (40 Hz) Stock solutions of antidiabetics were prepared at a concentration of 1 mg/mL in methanol. The standard solutions of 100 µg/mL were prepared from the mAU 2 No. Analyte% RSD RT % RSD area stock solutions. The excipient mixture 500 and the samples were filtered using 1Glipizide 0.0060.149 Agilent Captiva Premium Syringe Filter, 2Gliclazide0.006 0.219 3Glibenclamide 0.0240.115 regenerated cellulose membrane, 400 4Glimepiride 0.0260.153 15 mm diameter, 0.45 µm pore size 5Gliquidone0.038 0.150 (p/n 5190-5109). 300 6Repaglinide 0.0220.152 All solvents were LC grade. Fresh 1 ultrapure water was obtained from a 200 Milli-Q Integral system equipped with a 3 5 0.22 μm membrane point-of-use cartridge 4 (Millipak). 100 6 Columns 0 • Agilent ZORBAX Eclipse Plus C18 4.6 × 150 mm, 5 µm 2.5 5 7.5 10 12.5 15 17.5 20 min (p/n 959993-902) Figure 2. Six consecutive runs of six antidiabetic drug standards on an Agilent ZORBAX Eclipse Plus C18, 4.6 × 150 mm, 5 µm. • Agilent ZORBAX RRHD Eclipse Plus C18, 3 × 50 mm, 1.8 µm (p/n 959757-302) 3 To shorten the analysis time of the six No. Analyte% RSD RT % RSD area antidiabetic drug standards, the method 1Glipizide 0.034 0.450 mAU 1 was transferred to an UHPLC method 2Gliclazide 0.034 0.459 using an Agilent ZORBAX RRHD Eclipse 250 3Glibenclamide 0.027 0.568 Plus C18, 3 × 50 mm, 1.8 µm column. In 4Glimepiride 0.034 0.697 comparison to a 4.6-mm id column, it was 2 3 5Gliquidone 0.034 0.658 also possible to save solvent (over 85% 200 6Repaglinide 0.028 0.626 per analysis) using lower flow rates with the 3-mm column, but gaining the same 150 results. Figure 3 displays the UHPLC 5 analysis together with the precision results for retention time and area. 100 4 The RSD of retention time and area was 6 found to be below 0.04% respectively 50 0.7% for six consecutive runs. Regarding the over 10x shortening of the analysis 0 time, the RSDs of the UHPLC method 0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 min were still excellent. Figure 3. Six consecutive runs of six antidiabetic drugs standards using an Agilent ZORBAX RRHD Eclipse Both analytical methods were evaluated Plus C18, 3 × 50 mm, 1.8 µm. regarding linearity and limit of detection (LOD) and limit of quantitation (LOQ). Seven different concentration levels (from 100 µg/mL down to 0.14 µg/mL, 1:3 Table 1. Linearity and LOD/LOQ, a comparison between HPLC and UHPLC conditions. dilution) were prepared from the stock HPLC UHPLC HPLC LOD UHPLC LOD HPLC LOQ UHPLC LOQ solutions and the linear relationship was Analyte R² R² (pg) (pg) (pg) (pg) determined between the peak area and Glipizide 1 0.9999 66 38 221 127 the corresponding concentrations. LOD Gliclazide 1 0.9999 76 46 254 153 and LOQ were defined as the signal-to- noise ratio of 3:1 respectively 10:1. Table 1 Glibenclamide 1 0.9999 96 44 319 148 shows the results of the evaluation. Glimepiride 1 0.9999 121 80 403 268 Both methods showed very high linearity Gliquidone 1 0.9999 147 67 490 222 with coefficients of determination (R²) of Repaglinide 1 0.9999 469 214 1563 714 0.9999 for UHPLC and 1 for HPLC. LOD and LOQ were improved using the UHPLC conditions, double, for example, for glibenclamide. Table 2. Interference of seven tested excipients. Both methods were examined for Excipient Interference interference of seven of the most Silica - common excipients. Due to the Starch, soluble - hydrophilic properties of the excipient Talc - substances, resulting in a very early Magnesium stearate - elution, none of the excipients showed Cellulose - any interference (see Table 2). Polyvinylpyrrolidone - Hypromellose - 4 Both HPLC and UHPLC methods were HPLC and UHPLC method. Accuracy (TCM drug 1, TCM drug 2) were analyzed evaluated for their precision and accuracy was comparable between the HPLC and for the content of chemical antidiabetic regarding the calculated amount of the UHPLC method. Due to the shortening of drug substance. Figure 4 shows the six antidiabetic drug substances. For this the UHPLC method, the intra and interday chromatograms obtained from the experiment, 50 µg/µL per antidiabetic precision was slightly better for the HPLC samples compared to the standard substance was spiked into an excipient method. However, excellent precision mixture. The asterisks mark peaks, mixture, dissolved in methanol. Three was gained with both methods. resulting from the other ingredients of the replicates were analyzed on three capsules (main ingredient: bitter melon consecutive days to determine the One antidiabetic over-the-counter and other natural ingredients). accuracy as well as the intra and interday (OTC) drug sample (OTC diabetic precision. Table 3 displays the comparison drug) and two dietary supplements of accuracy and precision between the from traditional Chinese medicine Table 3. Precision and accuracy amount - HPLC versus UHPLC. HPLC UHPLC HPLC UHPLC Spiked HPLC UHPLC intraday intraday interday interday concentration accuracy accuracy precision precision precision precision Analyte (µg/mL) (%) (%) (%) (%) (%) (%) Glipizide 50 102.35 99.83 0.13 0.73 0.17 0.83 Gliclacide 50 99.09 100.79 0.04 1.13 0.75 1.24 Glibenclamide 50 98.35 101.55 0.03 0.85 0.21 0.94 Glimepiride 50 96.84 101.61 0.05 0.26 0.42 0.81 Gliquidone 50 98.79 100.20 0.07 0.32 0.42 0.92 Repaglinide 50 97.97 104.56 0.11 0.15 0.49 0.97 mAU * 3 200 TCM drug 1 175 * 150 3 TCM drug 2 125 2 100 OTC diabetic drug 75 1 50 2 3 5 Standard mixture 25 4 6 0 0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 min Figure 4.